
WHO has certified that Barbados has eliminated mother-to-child transmission of HIV. No infant was infected that way from 2022 to 2024, and 98% of pregnant women were tested and, if positive, treated.

In Isiro, DR Congo, the Ebola treatment center has grown from 40 to 50 beds with MSF, WHO has delivered more than a tonne of supplies, and patients are returning to the general hospital. A doctor who survived Ebola is back at work.

Gavi and UNICEF have secured a price of €5.50 a dose for the RTS,S malaria vaccine, about 40% lower, saving roughly US$50 million in 2027 to 2029. That could fund the full course for up to one million more children.

In the SEVUSMAART trial in Kenya and Zambia, sevuparin given with artesunate was safe and well tolerated in 23 children with severe malaria, and researchers found the dose to test next. Efficacy trials across Africa come next.

Brazil's health regulator Anvisa has approved a phase 1 trial of Vivaxin, a vaccine against Plasmodium vivax malaria developed by USP and UFMG. Recruitment of 48 healthy adults is due to start in January 2027.

UNICEF has handed 75,000 vials of medicine to health authorities in Khyber Pakhtunkhwa, where more than 10,500 leishmaniasis cases have been reported this year, over 4,400 of them in children under 16.

WHO's European experts have validated Albania and Armenia as having reached the region's hepatitis B control targets. Surveys found no infections among children aged 6 to 8 after more than 20 years of vaccination.

An AI-guided recipe kept mRNA vaccine particles stable for up to a year at room temperature and two months near body heat. The results so far come from cell and mouse studies.

WHO and partners have launched a roadmap to 2035 to cut deaths from pre-eclampsia and other high blood pressure disorders in pregnancy, which kill an estimated 42,000 women a year.

Volunteers in Masaka, Uganda, have received the first doses of ChAdOx1 BDBV, an Oxford-developed vaccine against Bundibugyo virus disease, a severe form of Ebola that has no licensed vaccine. The phase I trial will test safety and immune response.